Analysts Offer Predictions for Kalvista Pharmaceuticals Inc’s Q3 2021 Earnings (NASDAQ:KALV)

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) – Equities research analysts at SVB Leerink issued their Q3 2021 earnings per share estimates for Kalvista Pharmaceuticals in a research note issued on Monday, September 14th. SVB Leerink analyst J. Schwartz anticipates that the specialty pharmaceutical company will post earnings per share of ($0.75) for the quarter. SVB Leerink also issued estimates for Kalvista Pharmaceuticals’ Q4 2021 earnings at ($0.74) EPS and FY2022 earnings at ($3.60) EPS.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Monday, September 14th. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kalvista Pharmaceuticals had a negative return on equity of 31.21% and a negative net margin of 229.45%.

KALV has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating on shares of Kalvista Pharmaceuticals in a report on Thursday, July 2nd. Zacks Investment Research cut shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine cut shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $25.00 target price on shares of Kalvista Pharmaceuticals in a research note on Wednesday, July 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Kalvista Pharmaceuticals presently has an average rating of “Buy” and an average target price of $22.67.

KALV opened at $13.40 on Wednesday. The company has a market cap of $239.90 million, a price-to-earnings ratio of -8.17 and a beta of 2.44. The company’s 50 day moving average is $12.46 and its 200 day moving average is $11.13. Kalvista Pharmaceuticals has a 12-month low of $5.61 and a 12-month high of $18.96.

Several institutional investors have recently added to or reduced their stakes in KALV. Citigroup Inc. raised its position in shares of Kalvista Pharmaceuticals by 53.6% during the first quarter. Citigroup Inc. now owns 3,887 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 1,357 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Kalvista Pharmaceuticals by 155.6% during the first quarter. BNP Paribas Arbitrage SA now owns 4,604 shares of the specialty pharmaceutical company’s stock valued at $35,000 after buying an additional 2,803 shares during the last quarter. Invesco Ltd. bought a new stake in shares of Kalvista Pharmaceuticals during the first quarter valued at approximately $83,000. Alliancebernstein L.P. raised its position in shares of Kalvista Pharmaceuticals by 21.8% during the first quarter. Alliancebernstein L.P. now owns 12,300 shares of the specialty pharmaceutical company’s stock valued at $94,000 after buying an additional 2,200 shares during the last quarter. Finally, Spark Investment Management LLC bought a new stake in shares of Kalvista Pharmaceuticals during the first quarter valued at approximately $98,000. Hedge funds and other institutional investors own 89.09% of the company’s stock.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Further Reading: What is the definition of market timing?

Earnings History and Estimates for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.